Revision History
Lila Sciences · 8 revisions
Sizes are character counts of the article source. The signed number is the change from the previous revision.
Recent edit summaries
Detailed summaries recorded by editors. Generic maintenance summaries are omitted here; every recorded revision remains below. Dates describe the edit, not necessarily the event it covers.
- Correction: the October 2025 valuation of more than $1.3 billion was confirmed by the company to Reuters (not unconfirmed); Andrew Beam is a current Harvard faculty member; Gomez-Bombarelli is CSO of physical sciences and a co-founder; the mRNA efficiency claim is re-cited to its source (Contrary) and an unsupported "largest early-stage funding" superlative removed; quotes from Lila's September 2025 Series A post ("every step of the scientific method," "close the loop between reasoning and real-world verification") are re-cited to that post, and an unsourced "one of the most visible bets" assessment removed. Update: June 2026 Bloomberg report of Series B talks (about $2B at about $8.5B pre-money, not announced as closed), 2026 leadership roster, Lila Iris and Catalyst/Creation offerings, Alewife facility, September 2026 arXiv catalyst preprint, mRNA/CAR-T disclosures, NVIDIA BioNeMo and GTC Berlin, DOE Genesis Mission Phase I awards, recognition.
Version 8 · Oct 27, 2026, 07:22 AM
- Improve internal links (2026-10-13)
Version 7 · Oct 13, 2026, 10:11 AM
- Correction: resolve forward-looking claims whose stated deadline had passed, re-anchor stale as-of statements, and fix related citation and figure errors found in the same pass
Version 6 · Aug 1, 2026, 11:53 AM
- Added 6 contextual internal links
Version 5 · Jul 23, 2026, 04:00 PM